Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming
Group of 11 companies is focusing on biosimilar reimbursement and educational issues important to market formation.
You may also be interested in...
Biosimilars Forum’s New Executive Director Faces Down Challenge Of Interchangeability Confusion
Juliana Reed, who just moved from Pfizer to head the trade group, hopes scientific advances will eventually eliminate the need for the interchangeability designation, but for now the association is educating stakeholders in preparation for the 2023 launch of Humira biosimilars.
PhRMA Embraces Teva Across Brand-Generic Divide
PhRMA accepts Teva's request for membership; BIO rejected Teva five years ago.
Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself
FDA asks negotiators from the four industry groups to coordinate proposed changes as BsUFA renewal talks get underway.